Large cell neuroendocrine carcinoma (LCNEC)
Conditions
Interventions
A combined therapy of Bevacizumab plus Docetaxel
Sponsors
Toho University Omori Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically or Cytlogically confirmed large cell neuroendocrine carcinoma (LCNEC) 2) Stage IIIB/IV or postoperative recurrence 3) Previously treated platinum based chemotherapy 4) Patients aged 20 years or older 5) ECOG performance status of 0-1 6) Measureable region evaluable according to the RECIST(ver.1.1) 7) Adequate organ function 8) Patients who are considered to survive for more than 4 months 9) Written informed consent from the patient
Exclusion criteria
Exclusion criteria: Severe or uncontrollable systemic disease 2) Active infection 3) Active concomitant malignancy 4) Symptomatic brain metastasis 5) Uncontrollable pleural effusion, ascites, or pericardial effusion 6) History of GI perforation 7) Tendency to hemorrhages 8) Pregnancy, breast feeding and suspected pregnancy 9) Invasion to major vessel or cavitations of tumor 10) Uncontrollable hypertension 11) Inappropriate patients for this study judged by the physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival Safety Progression free survival | — |
Countries
Japan
Contacts
Public ContactKazutoshi Isobe
Toho University Omori Medical Center Department of Respiratory Medicine
Outcome results
None listed